Cutaneous melanoma · Lifileucel TIL therapy (Amtagvi, melanoma 3L+)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Track | aggressive |
|---|---|
| Linked regimen | REG-LIFILEUCEL-TIL-MELANOMA |
| ID | IND-MELANOMA-3L-LIFILEUCEL |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 |
| Diseases | DIS-MELANOMA |
| Sources | SRC-C14401-CHESNEY-2024 SRC-NCCN-MELANOMA-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. 3L+ aggressive-track cellular salvage. Ukraine access constraint dominant: international referral required (Iovance US authorized centers; EU pilot sites emerging — Spain, Netherlands, Germany). Loft cost USD ~515K for TIL product alone; total package USD 500-700K. Treatment-related mortality ~7% — patient selection critical. Position in algorithm: default "lifileucel_default" branch when both IO and BRAFi exhausted, OR BRAF-WT post-IO with no other actionable option.
Used By
Algorithms
ALGO-MELANOMA-METASTATIC-2L- ALGO-MELANOMA-METASTATIC-2L